Ängelholm, Sweden, June 21, 2017

Airsonett

Treatment with Airsonett® AIR4 has sustained benefit in children and adolescents with severe allergic eczema (atopic dermatitis)

Promising results from an independent prospective pilot study lead by Dr. Claudia Gore, Imperial College, London, was presented Tuesday afternoon at the ongoing EAACI congress in Helsinki.[1] The study showed that treatment with Temperature controlled Laminar Airflow (TLA; Airsonett) can lead to a significant clinical improvement in children and adolescents with severe allergic eczema, with accompanying reduction in medication usage.

Allergic eczema (also called atopic dermatitis) is a chronic inflammatory skin disease affecting up to 20% of children. Severe allergic eczema inflicts a substantial burden on patients and their families. Children and parents are burdened with time-consuming topical treatment regimens. In addition, many families have to deal with a significant loss of sleep related to night-time itching and scratching.

The TLA device has previously been shown to significantly reduce the amount of inhaled allergens and other potential trigger factors in the breathing zone over night, leading to decreased symptoms and improved quality of life in patients suffering from allergic asthma.[2-4]

The current study was designed to evaluate the effectiveness of overnight treatment with the TLA device (Airsonett) in children and adolescents with severe allergic eczema over a 12-month period. Fifteen children (2-16 years) with longstanding severe allergic eczema (atopic dermatitis) were followed during a 12-month treatment period. The study results included significant improvements in SCORring of Atopic Dermatitis (SCORAD) index, Investigator Global Assessment (IGA) and Family Dermatology Quality of Life index (FDQLI) after 12 months treatment. Importantly, the clinical improvement was accompanied by a reduction in the use of potent topical corticosteroids.

FOR MORE INFORMATION, PLEASE CONTACT:
Fredrik Werner, CEO, Airsonett AB
Tel: +46 708 494 862 E-mail: fredrik.werner@airsonett.eu

FOR ACCESS TO HIGH-RESOLUTION PICTURES, PLEASE CONTACT:
Annica Anderberg
Tel: +44 7787 123 556 E-mail: annica.anderberg@airsonett.eu

About Airsonett
Airsonett AIR4 is a CE marked class I device intended to be used for the alleviation of symptoms of allergy induced diseases such as allergic asthma. It adheres to relevant EU directives regarding design, function, safety and health requirements and has undergone rigorous clinical research as well as health economy studies. Airsonett AB is a Swedish-owned company. The main share owners are SEB Venture Capital, Industrifonden and Magnus Lundberg. For more information, visit www.airsonett.com

References:

1. Gore C et al. The overnight use of a temperature-controlled laminar airflow (TLA) device has sustained benefit for children with severe eczema. Abstract #0440, presented at the European Academy of Allergy & Clinical Immunology (EAACI) meeting 2017
2. Gore RB et al. Effect of a novel temperature-controlled laminar airflow device on personal breathing zone aeroallergen exposure. Indoor Air 2015;25:3644
3. Boyle RJ et al. Nocturnal temperature controlled laminar airflow for treating atopic asthma: a randomised controlled trial. Thorax 2012;67:215-221
4. Schauer U et al. Improved asthma control in patients with severe persistent allergic asthma after 12 months of nightly temperature-controlled laminar airflow (TLA): An observational study with retrospective comparisons. Eur Clin Respir J 2015, 2: 28531